Vistagen's Fasedienol Shows Clinically Meaningful Improvement in Social Anxiety in Open-Label Extension
VTGN sits 34% above its 52-week low of $0.198 on light trading volume (0.1× avg).
Summary
Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder. The drug was well-tolerated with no new safety signals, and exploratory efficacy showed clinically meaningful improvement on LSAS (31.4 points at Month 4) and SPIN (14.9 points at Month 4). The company also reported that fasedienol nasal spray was well-tolerated with no new drug-related safety findings after 12 months. This follows the June 2026 failure of the randomized portion of PALISADE-4 to meet its primary endpoint, making these OLE results a potential lifeline for the program. The company plans to meet with the FDA this quarter to discuss a new registrational Phase 3 trial. With a market cap around $10 million and going concern doubts, positive data could significantly shift sentiment, but the open-label design and exploratory nature temper conviction.
At the time of this announcement, VTGN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $0.20 to $5.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.